Bridgeway Capital Management’s Artiva Biotherapeutics ARTV Stock Holding History

Bridgeway Capital Management’s Portfolio ARTV Stock Details ARTV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$825K	Buy	85,000 +50,000	+143%	+$455K	0.01%	772
2026 Q1	$225K	Hold	35,000	–	–	﹤0.01%	1006
2025 Q4	$150K	Hold	35,000	–	–	﹤0.01%	1067
2025 Q3	$100K	Hold	35,000	–	–	﹤0.01%	1116
2025 Q2	$52.9K	Buy	+35,000	New	+$73.5K	﹤0.01%	1133

Other funds holding ARTV

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Bridgeway Capital Management's ARTV Position: Q2 2026 in Review

Bridgeway Capital Management increased its Artiva Biotherapeutics (ARTV) stake by 143% in Q2 2026, buying an estimated $455K and bringing the position to 85,000 shares worth $825K. The position accounts for 0.01% of the portfolio, ranked #772.

Bridgeway Capital Management first reported a position in ARTV in Q2 2025 and has held it in 5 quarters since. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

Bridgeway Capital Management held 85,000 shares of Artiva Biotherapeutics worth $825K as of Q2 2026.
Bridgeway Capital Management bought 50,000 Artiva Biotherapeutics shares in Q2 2026, an estimated $455K.
Artiva Biotherapeutics made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #772 holding.
Bridgeway Capital Management first reported a position in Artiva Biotherapeutics in Q2 2025 and has held it in 5 quarters since.
72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.